Effect of Etanercept on insulin sensitivity in nine patients with psoriasis

International Journal of Immunopathology and Pharmacology

Volumn 20, Issue 4, 2007, Pages 731-736

  Marra, Maurizio ^a   Campanati, A ^b   Testa, R ^a   Sirolla, C ^a   Bonfigli, A R ^a   Franceschi, C ^a,c   Marchegiani, F ^a   Offidani, A ^b  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Etanercept; Inflammation; Insulin resistance

Indexed keywords

ETANERCEPT; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; MALE; PRIORITY JOURNAL; PSORIASIS;

EID: 37749015604     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200702000408     Document Type: Article

References (20)

1. Reaven G.M. 1988. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595.
2. Hotamisligil G.S., N.S. Shargill and B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87.
3. Pickup J.C. and M.A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241.
4. Dandona P., A. Aljada and A. Bandyopadhyay. 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25:4.
5. Hotamisligil G.S. 2003. Inflammatory pathways and insulin action Int. J. Obes. 27(S):53.
6. Ofei F., S. Hurel, J. Newkirk, M. Sopwith and R. Taylor. 1996. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881.
7. Paquot N., M.J. Castillo, P.J. Lefebvre and A.J. Scheen. 2000. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 85:1316.
8. Bernstein L.E., J. Berry, S. Kim, B. Canavan and S.K. Grinspoon. 2006. Effects of etanercept in patients with the metabolic syndrome. Arch. Intern. Med. 166:902.
9. Dominguez H., H. Storgaard, C. Rask-Madsen, T. Steffen Hermann, N. Ihlemann, D. Baunbjerg Nielsen, C. Spohr, L. Kober, A. Vaag and C. Torp-Pedersen. 2005. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42:517.
10. Lowes M.A., F. Chamian, M.V. Abello, J. Fuentes-Duculan, S.L. Lin, R. Nussbaum, I. Novitskaya, H. Carbonaro, I. Cardinale, T. Kikuchi, P. Gilleaudeau, M. Sullivan-Whalen, K.M. Wittkowski, K. Papp, M. Garovoy, W. Dummer, R.M. Steinman and J.G. Krueger. 2005. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. USA 102:19057.
11. Gottlieb A.B., F. Chamian, S. Masud, I. Cardinale, M.V. Abello, M.A. Lowes, F. Chen, M. Magliocco and J.G. Krueger. 2005. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175:2721.
12. Weinberg J.M. 2003. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin. Ther. 25:2487.
13. American Diabetes Association. 2004. Diagnosis and classification of diabetes mellitus. Diabetes Care 27(S):5.
14. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21:1011.
15. Matthews D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412.
16. Katz A., S.S. Nambi, K. Mather, A.D. Baron, D.A. Follmann, G. Sullivan and M.J. Quon. 2000. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85:2402.
17. Berth-Jones J., K. Grotzinger, C. Rainville, B. Pham, J. Huang, S. Daly, M. Herdman, P. Firth and K. Hotchkiss. 2006. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br. J. Dermatol. 155:707.
18. Finlay A.Y. and G.K. Khan. 1994. Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19:210.
19. Hundal R.S., K.F. Petersen, A.B. Mayerson, P.S. Randhawa, S. Inzucchi, S.E. Shoelson and G.I. Shulman. 2002. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109:1321.
20. Testa R., F. Olivieri, A.R. Bonfigli, C. Sirolla, M. Boemi, F. Marchegiani, M. Marra, S. Cenerelli, R. Antonicelli, A. Dolci, G. Paolisso and C. Franceschi. 2006. Interleukin-6-174 G > C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res. Clin. Pract. 71:299.